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The analytical performance and practicability of the Boehringer
Mannheim (BM)/mtaci 91 analysis system have been assessed
in a multicentre evaluation, which involved six laboratories from
European countries. Analytes commonly used in classical clinical
chemistry were tested in a core programme, which mainlyfollowed
lhe ECCLS guidelines. In addition, a satellite programme covered
other analytes, such as proteins, drugs and urine analytes. In total,
the study comprised more than 100 000 data items collected over a
three-month period. The evaluation was supported with ’Computer
Aided Evaluation’ (CAEv) and telecommunications.
Acceptance criteria for the results were established at the
beginning ofthe study. Nearly all ofthe analytes met the imprecision
limits." within-run imprecision (as CVs) was 2l/of or enzyme and
substrate assays, l%for ISE methods and 5l/ofor immunoassays;
between-day imprecision was 3l/of or enzyme and substrate assays,
2o//o for ISE methods and 10% for immunoassays.
No relevant drift effects (systematic deviation >_ 3O//o) were
observed over eight hours. The methods were linear over a wide
range. Sample-related and reagent-dependent carry-over can be
reduced to a negligible amount by integration of a software-
controlled wash-step.
Endogenous interferences were found for creatinine
method) and uric acid assays (caused by bilirubin), for creatine
kinase, creatine kinase MB isoform and 7-glutamyltransferase
(caused by haemoglobin), andfor immunoglobulin A (caused by
lipaemia)
Accuracy was checked by an interlaboratory survey, recovery
studies in control materials and method comparison studies. The
survey showed that, with the exception of cholesterol and iron in
two laboratories, the recovery of analytes did not deviate by more
Correspondence about this paper should be addressed to Dr Z. aman at the
University Hospitals, Leuven.
than 5%. Sixty-six of the 77 method comparisons performed met
the acceptance criteria. The deviations of the remaining 11 results
could be explained by differences in either calibration, application
or by the use of different methods.
Practicability was assessed using a questionnaire which covered
all of the important aspects of an analysis system in the clinical
laboratory. Twelve groups ofattributes out of14 were rater higher
for the BM/Hitachi 911 than for the present situation in the
laboratories concerned. Especially high scores were given for the
versatility group.
The acceptance criteria for the analytical performance of the
BM/Hitachi 911 analysis system were fulfilled in all laboratory
segments with few exceptions. The practicability exceeded the
requirements in most of the attributes. The results of the study
confirmed the usefulness of the system as a consolidated workstation
in small- to medium-sized clinical laboratories and in STAT
laboratories, or as an instrumentfor special analytes like proteins
and drugs, orfor urinalysis in large laboratories.
Introduction
The Boehringer Mannheim (BM)/Hitachi 911 analysis
system is the most recent medium-sized analysis system
to be introduced to the market by Boehringer Mannheim
GmbH. In addition to the well-accepted analytical
performance and reliability of previous BM/Hitachi
analysis systems, the new instrument has features making
it attractive to different sections of clinical laboratories.
These are in routine and emergency analysis (STAT),
homogeneous immunoassays for the determination of
proteins and drugs and urinalysis. Therefore the BM/Hitachi
911 has to be extremely flexible. This is achieved by
incorporation of features such as automatic recognition
of four different barcodes for sample identification, use of
up to four reagents per test, variable reaction time,
random analysis of serum and urine specimens using the
same calibration curve, fully automated predilution of
specimens and automatic calibration.
The versatility of the new instrument required the design
of a comprehensive evaluation. Six European laboratories
participated in the multicentre evaluation. Analytes of
classical clinical chemistry were tested in a core pro-
gramme, which mainly tbllowed the ECCLS guidelines
[1]. In addition, the behaviour of the system in different
laboratory sections was tested in a satellite programme.
The evaluators ran a much less extensive satellite
evaluation in order to maintain an acceptable cost/benefit
ratio. In total, the study included more than 100 000 data.
Processing and analysis of the large data volumes was
managed with a program system called ’Computer Aided
Evaluation’ (CAEv) and telecommunications.
CAEv integrates the definition of study protocols,
performance of experiments in the laboratory, online/
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offiine data transmission and the immediate assessment
and evaluation of the results [2]. The program runs on
a standard PC under MS-DOS. It had previously been
successfully applied to the multicentre evaluation of the
BM/Hitachi 747 analysis system [3].
Telecommunications were used for the first time in an
international multicentre evaluation. Installation of the
necessary facilities in the participating laboratories
allowed rapid and simple transfer of data to the centre
coordinating the study.
The assessment of practicability was a further goal of the
evaluation of the BM/Hitachi 911. The evaluators
answered 200 questions each about the system. All results
of the multicentre evaluation are presented in this paper.
Description of the instrument
The BM/Hitachi 911 is a medium-sized selective access
analyser with a capacity for 35 different tests, including
three ion selective electrode (ISE) methods for sodium,
potassium and chloride. The instrument specifications are
listed in table 1. The throughput is 360 photometric
tests/h; this is reduced by automatic sample predilution
or additional wash steps which may be needed to eliminate
reagent carry-over. The pipetting cycle for photometric
tests, for the automatic predilution and for the wash steps,
is 10 and for the ISE methods 20 s.
Various measurements and calibration procedures that
can be applied are:
(1) Endpoint measurements with/without sample blank
within 16 min.
(2) Kinetic determinations with sample or substrate start
(49 measuring points within 16 min).
(3) ’Fixed-time’ measurements (two-point kinetic).
(4) Combination of kinetic and endpoint measurements
with ’twin tests’.
(5) Potentiometric measurements with the ISE units
within 20 at 37C.
(6) Serum indices for the characterization of haemolytic,
icteric and lipaemic sera.
(7) Prozone check (detection of antigen excess).
(8) Linear and four nonlinear modes of calibration, the
frequency of which is controlled by the instrument
(auto-calibration).
Table 1. BM/Hitachi 911 instrument specifications.
Type of instrument
2 Test channels
3 Test procedures
4 Throughput
5 Sampling system
6 Sample pipettor
7 Reagent cooling
8 Reagent bottles
9 Reagent dispenser
10 Mixing procedure
11 Reaction rotor
12 Reaction cuvettes
13 Reaction cycle
14 Temperature control
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Discrete selective multianalyser.
32, with ISE-module 35.
Endpoint, endpoint with sample blank, kinetic with serum or substrate start, fixed-time kinetic,
combination of two endpoint tests, endpoint and kinetic tests, two kinetics tests performing
two tests in one cuvette, two prozone check procedures, measurement with ISE, linear
calibration and four nonlinear modes of calibration, autocalibration, two-point recalibration,
isoenzyme calibration, serum indices indicating haemolytic, icteric and lipaemic specimens.
Maximum 360 photometric tests/h, with ISE-module 720 tests/h.
Turntable with 115 positions in total, arranged in three concentric rings:
--50 positions in the outer ring for routine samples
--40 positions in the middle ring
3 for wash solutions
--20 for STAT samples
--17 for standards/calibrators
--25 cooled positions in the inner ring for 17 standard and 8 control samples.
Primary tubes from 13 to 16 mm diameter and 75 to 100 mm length, secondary sample cups
with 2 ml and microcups with 0"5 ml maximum volume. Barcode identification of primary
tubes. Codes: code bar NW 7, code 32, 2 out of 5 interleaved, code 128. Different codes and
different tube sizes can be used within one sample disk.
3 to 50 gl (in steps of gl), imprecision < 1; for ISE same pipettor 15 gl for the three
determinations of Na, K, C1.
Cold water circuit, refrigerator temperature 5 to 15C.
20, 50 and 100 ml sizes, 2 reagent disks with 33 bottle positions, one position reserved for
cuvettes rinsing solution. Disk for reagent and 4, disk 2 for reagent 2 and 3.
2 reagent pipettors for dispensing reagents to 4, 50 to 350gl (in steps of lgl).
2 stirrers mix the reaction solution independently after addition of each reagent.
Turntable with 120 cuvettes; half rotation (60 cuvettes + 1) in 10s one working cycle.
Special plastic cuvettes, semidisposable.
Volume required: minimum 250 lal, maximum 500
Optical path length: 6 mm.
3, 4, 5, 10 and 16 minutes reaction time corresponding to 10, 13, 15, 31 and 49 measuring
points. Average time between two measuring points: 20 s.
Water-bath, 37 0"IC.Z. Zaman et al. Multicentre evaluation of the Boehringer Mannheim/Hitachi 911 Analysis System
Table 1 (continued).
15 Photometer
16
17 Data processing
18 Water supply
Ion-selective electrodes
19 Ambient temperature
20 Relative humidity
21 Physical dimensions
22 Weight
--Single beam photometer with 12 available wavelengths: 340, 376, 415, 450, 480, 505, 546,
570, 600, 660, 700 and 800 nm; mono- or bichromatic measurement with free selectable
wavelengths combination.
--Light source: halogen lamp. Detector- silicone photodiode.
--Wavelength adjustment: fixed, via a grating chromator, inaccuracy at 340 nm 2 nm and
at 405 to 800 nm + 5 nm.
--Half band width: 4 nm in the UV range
10 nm in the visible range
--.Photometric range of linearity: A -0- 2"5 at 340 nm
--Photometric resolution: A--0"0002
--.Photometric inaccuracy: max. 1 at 2"0 abs.
--Indirect potentiometry; flow-through electrode with liquid membrane.
--.Reference electrode" liquid membrane
---Dilution ratio" 1" 31
--Incubation temperature: 37 0"IC
--Calibration: 2-point with compensation
Measuring cycle: 20
--.Measuring range in serum in urine
Na
/ 80-180 10-250 mmol/1
K
/ 1"5-10 1-100 mmol/1
C1- 60-120 10-250 mmol/1
--Consumption of ISE solution per sample:
diluent" 450 Itl
internal standard: 1050 Itl
KC1 solution 130 Itl
--.Data input: via alpha numeric keyboard and item select keys.
---Data control: CRT 14 inches colour monitor.
-Data output: matrix printer, 80 characters per line, 220 characters per second.
-2 floppy disk drives, 3"5 inches, system disk and data disk for storage of 800 routine
samples and 200 STAT samples.
--Interface" RS 232 C. Bidirectional link with a host computer.
--Internal reservoir with an external supply.
Quality" _< ItS
Consumption during operation: 30 1/h
15 to 32C
45 to 85
Analyscr unit Operator unit
Width 1"03 m 0"48 m
Depth 0"76 m 0"65 m
Height 1-17 m 1"25 m
Approx. 350 kg
The manufacturer provides an application disk to load
and store the application settings for the barcoded system
reagents. These can be inserted in any free position of the
reagent disk. For the use of non-barcoded reagents, the
operator must define the appropriate application settings.
Specimens (3-50 lal volume per test) are processed either
from primary tubes (5-10 ml), secondary cups (2 ml) or
microcups (500 lal). The primary tubes can be identified
by tbur different types of barcodes. The RS 232 interface
allows a bidirectional communication to a host computer.
One hundred and twenty plastic cuvettes (d 6 mm) are
arranged on a rotor which rotates in a water bath at 37C
(__0"IC). The cuvettes pass through the beam of the
photometer every 20 (12 fixed wavelengths between 340
and 800 nm, mono- or bichromatic). The photometric
range of linearity at 340 nm extends to an absorbance
of 2.5.
Two pipettors (50-350 gl) transtir the reagent into a
cuvette. The average reagent consumption is 300 lal per
determination.
Up to four reagents can be pipetted per test. For several
STAT tests the second reagent is added 1"3 min after the
sample pipetting and for routine tests after 5 min. If
necessary, a fourth reagent can be pipetted after 10 min.
The results ofeight STAT tests are available within 6 min.
Materials and methods
Inslrumenls and reagenls
The methods and instruments used in the study are listed
in table 2. The same lot of reagents was used in all
evaluation centres for each method. Reagents ti0r the
BM/Hitachi instrument were available in system packs
containing barcoded bottles.
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Table 2. Analytes, methods and comparison instruments.
Abbrevi- Method on
Analyte ation BM/Hitachi 911 Comparison instruments Comparison methods
Pancreatic PAMYL
a-amylase
Aspartate amino- ASAT
transferasc
Creatine kinase CK
Creatine kinase CK-MB
MB isoform
7-Glutamyl- GGT
transfcrase
fl-N-Acetylgluco- BNAG
saminidase
Calcium CA
Cholesterol CHOL
Crcatininc CREA
Iron FE
Fructosamine FRU CrI"
Total protein TP
Uric acid UA
C-Reactive CRP
protein
Fcrritin FT
Immuno- IGA
globulin A
Transferrin TF
Albumin in MAU
urine
Phenobarbital PHEBA
Phenotoin PHENY
Thcophyllinc THEO
Digoxin DIG
Ethyliden-G7 PNP as substrate (EPS)
According to IFCC and standard
optimized
Standard optimized
Standard optimized,
immunoinhibition
L-7-glutamyl-3-carboxy-4-nitroanilide
as substrate
Chlorophenol red (CPR)-NAG as
substrate
o-Cresolphthalein complexone
Cholesterol oxidase/
p-aminophenozone
Jaff6 (kinetic) without deproteinization
FerroZine without deproteinization
Reduction of nitroblue tetrazolium
chloride
Biuret
Enzymatic PAP
Turbidimetry
Turbidimetry
Turbidimetry
Turbidimetry
Turbidimetry
Homogeneous immunoassay,
CEDIA(R) Phenobarbital
Homogeneous immunoassay,
CEDIA Phenytoin
Homogeneous immunoassay,
CEDIA’- Theophylline
Homogeneous immunoassay,
CEDIA(R) Digoxin
Sodium NA ISE
Potassium K ISE
Chloride CL ISE
BM/Hitachi 704, 747
BM/Hitachi 704, 747
BM/Hitachi 717, 737, 747
BM/Hitachi 717, 747
BM/Hitachi 717, 737, 747
COBAS (R) Fara (Hoffmann-
LaRoche)
BM/Hitachi 747,
Atomic absorbance
spectrometer
Perkin Elmer 1100 B
BM/Hitachi 704, 747
BM/Hitachi 704, 717,747,
CX3 (Beckman)
BM/Hitachi 704, 747,
COBAS(R) Fara (Hoffmann-
LaRoche)
Isamat(R)
BM/Hitachi 704, 717, 747
BM/Hitachi 704, 717, 747
Behring Nephelometer
Stratus(R) II analyser
Behring Nephelometer
ARRAY (R) analyser
(Beckman)
COBAS(R) Fara (Hoffmann-
LaRoche),
ARRAY (R) analyser
(Beckman)
Manual
Abbott TDx
Abbott TDx
Abbott TDx
Abbott TDx
BM/Hitachi 747, CX3
(Beckman),
Flame spectrometer SCM
6341 (Eppendorf)
BM/Hitachi 747, CX3
(Beckman),
Flame spectrometer SCM
6341 (Eppendorf)
BM/Hitachi 747, CX3
(Beckman),
Chloride analyser 925
(Corning)
Same as BM/Hitachi 911
Same as BM/Hitachi 911
Same as BM Hitachi 911
Same as BM Hitachi 911
Same as BM Hitachi 911
Same as BM/Hitachi 911
Same as BM/Hitachi 911
Atomic absorption
spectroscopy
Same as BM/Hitachi 911
Same as BM/Hitachi 911
Same as BM/Hitachi 911
Same as BM/Hitachi 911
Same as BM/Hitachi 911
Same as BM/Hitachi 911
Fixed-time nephelometry
Fluorescence immunoassay
Fixed-time nephelometry
Rate nephelometry
Turbidimedtry
Rate nephelometry
Radioimmunoassay
Fluorescence polarization
immunoassay
Fluorescence polarization
immunoassay
Fluorescence polarization
immunoassay
Fluorescence polarization
immunoassay
ISE
Flame atomic emission
spectrometry
ISE
Flame atomic emission
spectrometry
ISE
Coulometry
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Control materials
Imprecision and quality control studies were performed
with lyophilized control sera (Boehringer Mannheim
GmbH) and control urines (Boehringer Mannheim
GmbH, Bio-Rad). Detailed information is shown in the
appendix (table 10).
Calibration
During the familiarization period, a fixed-factor was
determined for the enzyme tests in three independent
calibration runs per day on three consecutive days.
The same lot of the calibrator for automated systems
(Boehringer Mannheim GmbH) was used for this purpose.
The mean of the nine calibration runs was then taken as
the factor, provided that the range of all results did not
exceed 3 of the mean.
During experiments for the between-day imprecision and
method comparison (21 working days) autocalibration of
the analytical system was tested. The autocalibration is
triggered by an analyte-dependent calibration interval.
In order to avoid any additional effects on the results, a
’start-up’ calibration was activated before the remaining
experiments. Detailed information about the calibrators
employed is shown in the appendix (table 10).
Evaluation protocol
The versatility ofthe BM/Hitachi 911 analysis system was
tested in a core programme and a satellite programme.
The core program had been used for evaluations of
the BM/Hitachi 704, 717 and 747 analysis systems
[-5].
The 13 analytes tested in the core programme were
pancreatic 0c-amylase, aspartate aminotransferase, creatine
kinase, 7-glutamyltransferase, calcium, cholesterol, crea-
tinine, iron, total protein, uric acid, sodium, potassium,
and chloride. This programme included a familiarization
period, an initial trial and a main trial. The protocol of
the main trial is shown in table 3. The main trial was
split between two groups, each consisting of three
laboratories, which tested the same set of analytes. For
the studies of linearity, drift and sample-related carry-
over, the different methods were divided between the six
evaluators.
The satellite programme covered other analytes such as
proteins (C-reactive protein, ferritin, immunoglobulin A,
transferrin), drugs (phenobarbital, phenytoin, theophyl-
line, digoxin) and urinalysis (albumin, /-N-a.cetyl-
glucosaminidase, creatinine, sodium, potassium, chloride).
In addition, creatinine kinase MB isoform and fruc-
Table 3. Protocol of the multicentre evaluation (core programme, main trial)*.
Imprecision
Within-run
On three different days, each day one run with 21 aliquots
--:Fhree control materials with different concentrations of the analyte.
--.One human serum pool at the decision level.
Between-day
Three control materials with different concent’rations of the analyte over 21 days
(evaluation and comparison instrument).
Drift
Two control sera and the calibrator were analysed every 30 min over 8 h to test eight methods (aspartate aminotransferase,
creatine kinase, 7-glutamyltransferase, calcium, iron, creatinine, total protein and uric acid).
-At zero hour, triplicate measurements were performed and the median was taken as the base value.
The percentage recovery of the base value was taken for assessing drift effects.
Analytical range limits [7]
--A high level sample was diluted with a low level sample to obtain a series of eleven concentrations with two being the baseline
samples and nine intermediate concentrations.
--Triplicate measurements on the 11 concentration levels were performed and the median for each level was calculated.
--The regression line (Passing/Bablok regression) was calculated using a range covering five concentration levels which was
assumed to be linear.
--The target values for all concentration levels were calculated from the regression lines.
Carry-over
Sample-related
Model of Broughton [ 11]:
---Measurements of five aliquots of a high-concentration sample (hi"" "hs) are followed by
--Measurements of five aliquots of a low-concentration sample (11" "15). The experiment is repeated 10 times.
If a carry-over effect exists, 11 is the most influenced, 15 the least influenced aliquot.
Reagent-dependent:
One control material was used.
Assay A influences assay B.
* For details, see reference [3]. (continued)
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Table 3 (continued).
--.Carry-over caused by the cuvettes
In a first step, reagents for assay A were requested 21 times. Just after the dispensing of the reagents for the 21st aliquot, the
analyser was stopped. In a second step, reagents for assay B were requested 42 times. The first 21 determinations were performed
in the cuvettes which previously had contained the reagents for assay A. These determinations would show carry-over effects
whereas the last 21 determinations would be uninfluenced. The difference of the medians of both series was the carry-over.
--.Carry-over caused by reagent probes and stirrers
Assay B was carried out 21 times. In the second step test A and B were alternately performed 21 times. The carry-over was the
difference between the medians of both series.
Interference
Protocol of Glick [8]
A specimen with concentrations at the decision level was spiked with the interfering substance and 10 serial dilutions were prepared
with the same baseline specimen. The different analytes were measured in triplicate. The percentage recovery of the baseline value
for each concentration level was calculated.
Accuracy
Calibration
The calibrators of BM/Hitachi 911 and of the comparison instrument were both run on each instrument.
Quality control in three control materials
--Median, calculated from the second of duplicate measurements over 21 days.
Interlaboratory survey
--One control material with concentrations not known to the evaluators.
--Median, calculated from the second of duplicate measurements over 10 days.
Method comparison in fresh human specimens
--10 to 15 specimens were analysed each day for 10 days on the BM/Hitachi 911 and on the comparison instruments. The total
number of specimens covered the entire analytical range.
--Comparison of the methods by calculation of the Passing/Bablok regression line [10-].
In the satellite programme within-run imprecision was determined using one or two control materials and one human pool. Between-day
imprecision was studied over 10 days with one or two control materials.
Drift, linearity, carry-over and interference studies were carried out only for selected analytes.
tosamine assays were run in this part of the evaluation
study. The results of these analytes are presented together
with those of the core programme.
The protocol included quality specifications which were
agreed at the evaorators’ first meeting: these are described
later in this paper.
Assessmenl of praclicabilily
Practicability was assessed with the aid of a recently
published questionnaire [6] comprising about 200 ques-
tions which covered all important aspects of an analysis
system in the clinical laboratory. The questions were
summarized into 14 groups, as shown in table 4. They
were related to the installation of the analyser, organiza-
tion of work, quality assurance and miscellaneous
characteristics. A first version of the questionnaire had
already been used for the assessment of practicability of
BM/Hitachi 747 [3].
Grading was in comparison with the evaluators’ present
laboratory situation. The assessment was based on a scale
from 0 to 10: a score of 0 meant unimportant, useless or
poor, and a score of 10 absolutely necessary or excellent.
A score of 5 could be interpreted as being acceptable or
comparable with the present laboratory situation. The
grading was divided into three classes. Scores of up to 3"3
meant ’did not meet the requirements’, scores from 3"4
to 6"7 ’meets the requirements’, and scores from 6"8 to l0
’exceeded the requirements’.
Results
Imprecision
Acceptance criteria for imprecision were based on
statistical error propagation [3]. For within-run impre-
cision in participating laboratories the median of the CVs
should not exceed 2 for classical clinical chemistry
analytes (enzymes and substrates) in serum (only in the
tables is a differentiation made between serum and
plasma) and urine at all concentrations tested. The
accepted CV was reduced to 1 for the determination of
electrolytes by ISE. Taking into consideration the
problems associated with immunoassays, such as nonlinear
calibration or analytical sensitivity, it was agreed that
CVs of less than5 would be acceptable for these assays.
Within-run imprecision data based on results from all the
control sera from all laboratories are shown in figures 1-3,
and data for individual control sera are given in the
appendix (table 11). The medians of all analytes met the
acceptance criteria, except for phenytoin and digoxin in
the low level control. In individual control sera, results
exceeding the acceptance limits were obtained for
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Table 4. Assessment of practicability--groups of attributes.
Number
of items
PAMYL
Contents ASAT
CK
CK MB
GGT
Installation conditions
(space, power and
cA
water supply, waste, CHOL
noise) CREA
Location of instrument FRUCT
components
Operation (demand on
E
skills) T
Training course uA
Instruction manual
Duration
Ck
Availability
Tray
Loading
Vessels
Predilution
Volumes
Volume detection
Identification
Preparation
Loading
Identification
Stability
Exchange
Volume
Available tests
Test request
STAT procedure
Rerun
Result presentation
Throughput
Startup time
STAT time
Calibration
Operator time
Installation
(1) Environment 10
(2) Spatial arrangements 14
(3) Training/operation 14
Organization of work
(4) Start-up/shut-down 5
(5) Sample processing 31
(6) Reagent handling 17
(7) Work flow 23
(8) Timing 7
Quality assurance
9) Monitoring
10) Calibration 23
11) Quality control 12
Miscellaneous
(12) Data processing
environment
(13) Versatility
(14) Maintenance/
troubleshooting
15
15
range
median
cv [%1
Figure 1. Within-run imprecision for classical clinical chemistry
analytes and electrolytes, based on control material data from all
laboratories in the study.
[%1
high
Figure 2. Within-run imprecisionfor homogeneous immunoassays,
based on control material data from all laboratories.
Sample processing
Reagent processing
CREA Measuring process
Temperature control
Photometer control
MAU
Materials
Monitoring -
NAG
Procedure NA
Frequency
Number of controls K
Statistics
Real time/daily/ CL
cumulative
Alarms
Presentation
Hardware
Software
Communication
Analysis modes
Ease of applications
Duration and frequency
Combinations of
maintenance functions
Volumes tbr priming
Trouble-shooting
Alarms
Availability of technical
service
Power break-down
cv [%1
range
median
Figure 3. Within-run imprecision for analytes in urine, based on
control material data from all laboratories.
cholesterol, iron, sodium, potassium, chloride and for
albumin in urine.
All analytes which had not met the quality specifications
in control materials showed acceptable CVs in human
materials (table 5). Only the CV of creatine kinase MB
isotbrm exceeded the acceptance criteria.
Between-day imprecision was defined as acceptable if
median CVs for electrolytes were _<2, for homogeneous
immunoassays _< 10 and for the remaining analytes
investigated in serum and urine _<3.
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Table 5. Within-run imprecision in a normal human serum,
plasma or urine pool (N 21). The results of the pools with
concenlrations close to the decision level are shown.
Analyte Unit Mean CV
Pancreatic a-amylase U/1 71 1.7
Aspartate aminotransferase U/1 30 1.3
Creatine kinase U/1 149 0.8
Creatine kinase, MB isoform U/1 10 3.1
7-Glutamyltransferase U/1 46 0.9
Calcium mmol/1 2"2 0.9
Cholesterol mmol/1 5.1 1.7
Creatinine gnol/1 99 1.6
Fructosamine gmol/1 250 1.4
Iron gmol/1 13 1.8
Total protein g/1 70 0.4
Uric acid gmol/1 350 1.0
Sodium mmol/1 141 0.5
Potassium mmol/1 4.0 0.6
Chloride mmol/1 101 0.6
C-Reactive protein mg/1 14 3"2
Immunoglobulin A g/1 1.8 2"5
Ferritin gg/1 239 2"2
Transfcrrin g/1 2"6 2"0
Phenobarbital gg/ml 16 2"8
Phenytoin gg/ml 8"6 2"9
Theophylline gg/ml 12 3.0
Digoxin ng/ml 1.9 4.0
fi-N-Acctylglucosaminidase* U/1 10 0.6
Creatinine* mmol/1 1.0 1.0
Albumin* mg/1 33 1.4
Sodium* mmol/1 110 0.4
Potassium* mmol/1 35 0.5
Chloride* mmol/1 96 0.5
*Analytes in urine.
The medians and ranges of CVs in control materials
analysed on BM/Hitachi 911 are shown in figures 4-6;
results obtained in individual control sera are presented
in the appendix (table 11). The medians met the defined
quality specifications in all cases. Individual CVs exceeding
the acceptance criteria were obtained for calcium,
cholesterol, creatinine, sodium, chloride, phenytoin,
digoxin in serum and tbr albumin in urine. The results
of the comparison instruments were of the same order as
those of BM/Hitachi 91 (data not shown).
Analytical range limits
It was desirable for the measuring range to cover the
greatest part of the physiological and pathophysiological
range. Analytical range limits were established by
determining the difference between the measured values
and the target values from the dilution experiments as
described by Bablok [7]. In the upper range, a method
was defined to be linear if this difference was less than
5. The lower range was judged on the basis of such
pragmatic considerations as absolute differences between
measured and target values, and the diagnostic relevance
of these differences. In the case of multi-point calibration,
a method could be called linear if a change in the target
concentration led to a proportional change in the
measured concentration.
A wide linearity range was obtained for all clinical
PAMYL
ASAT
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Figure 4. Between-@ imprecision for classical clinical chemistry
analytes and electrolytes, based on control material data from all
laboratories.
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Figure 5. Between-day imprecision for homogeneous immuno-
assays, based on control material data ,from all laboratories.
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Figure 6. Between-day imprecision for analytes in urine, based
on control material data from all laboratories.
chemistry analytes in serum (table 6). The lower limit
tested for creatinine and calcium was found to be
30 gmol/1, and 0"3 mmol/1, respectively.
In urine, the required high linearity ranges were reached
for all analytes. Linearity in the low range was analysed
for albumin and sodium only. The albumin method was
found to be nonlinear below 25 mg/1 and the sodium
determination below 10 mmol/1.
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Table 6. Analytical ranges on the BM/Hitachi 911.
Sample
Analyte material Unit
Range
Tested between Found between
Aspartate aminotransferase serum
(IFCC method)
Creatine kinase serum
7-Glutamyltransferase serum
Pancreatic a-amylase serum
Calcium serum
Cholesterol plasma
Creatinine serum
Iron serum
Total protein
Uric acid
C-Reactive protein*
Immunoglobulin A
]3-N-Acetylglucosaminidase
Creatinine
Albumin
Sodium
Potassium
Chloride
plasma
plasma
serum
serum
urine
urine
urine
urine
urine
urine
U/1 14 870 14 870
u/
u/1
u/1
mmol/1
mmol/1
gmol/1
gmol/1
g/1
gmol/1
mg/1
g/1
U/1
mmol/1
mg/1
mmol/1
mmol/1
mmol/1
l0 -1520 l0 -1520
l0 -1250 l0 -1250
16 -2400 16 -2400
0 6 0.3- 6
2"9- 21.5 2"9- 21.5
0 -2000 30 -2000
0.9- 20 0.9- 20
10 215 10 215
8 175 8 175
0 -1200 0 -1200
0 25O 0 25O
6.3 6.0
0 78 0 78
1.5- 23 1-5- 23
0 5O0 2O 5OO
0 2OO 10 2OO
0 115 0 115
0 215 30 215
*Multi-point calibration, see discussion in text.
Drift effects were not accepted if a systematic deviation
from the initial value exceeded 3. Over an eight-hour-
period, no drift effects were observed in any of the 10
methods tested.
Calibration stability
Calibration stability based on individual calibration
frequency claims was observed over a period of21 working
days. No deviations in recovery exceeding3 were found.
Carry-over
Carry-over effects were assessed on the basis of the
observed change in recovery of an analyte. Instead of
adapting an individual deviation for each analyte it was
decided to use the within-run imprecision system perform-
ance. This was defined as a change of less than twice the
standard deviation being acceptable.
Sample-related carry-over was only tested for analytes
with a large physiological range and between urine and
serum specimens. For the potassium assay, a slight
carry-over effect (0"17 mmol/1) was observed from urine
to serum with a concentration ratio of77:1 (table 7). This
was rated as being of no clinical relevance.
Previous experience with BM/Hitachi systems had revealed
reagent dependent carry-over caused by the cuvettes for
the combination triglycerides/lipase. This effect was
avoided by activating a special wash solution step within
the normal cleaning procedure for the cuvettes on
BM/Hitachi 91 1.
Carry-over caused by the reagent probes and the stirrers
was tested for the combinations triglycerides/lipase and
aspartate aminotransferase/lactate dehydrogenase. This
resulted in an elevation of lipase activities by about
400 U/1 and of lactate dehydrogenase activities by about
30 U/1. Activation of a software-controlled wash-step for
these combinations reduced the carry-over effects to a
negligible amount < 10 U/1).
Interferences
According to Glick et al. [8], a method is resistant to
interferences if the deviation between the baseline value
and the measured value is less than 10. Only methods
not fulfilling this acceptance criterion are shown in the
interferograms ofbilirubinaemia, lipaemia and haemolysis
(figures 7-9).
Of the 13 methods tested only two showed interference
by bilirubin. Decreased values were found for the
creatinine (Jaffa method) and for the uric acid assays at
200 200
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50 100 150 200 250 300 350 400
Bilirubin [[Jmol/I]
Figure 7. Interference of bilirubin. The hatched zone represents
90 to 110% recovery of the baseline value. Analytes tested were:
creatine kinase, 7-glutamyltransf erase, creatinine, totalprotein, uric
acid, sodium, potassium, chloride, C-reactive protein, immuno-
globulin A, theophylline, phenobarbital, and phenytoin.
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Table 7. Sample-related carry-over.
Analy e Median Median
(sample of high of low
materials) Unit concentration concentration
Standard
Ratio Median of deviation
h" 11 -15 13, 1,, 15
Creatine kinase U/1 6 282 12.0
(serum/serum)
Ferritin gg/1 5 480 196
(serum/serum)
Creatinine gmol/1 35 100 58.1
(urine/plasma)
Albumin mg/1 54 300 16.5
(serum/urine)
Albumin mg/1 39 400 21.3
(plasma/urine)
Potassium mmol/1 224 2.9
(urine/serum)
Potassium mmol/1 161 4.0
(urine/plasma)
524 0.30 0.42
28 0.80 12.8
604 0.40 1.25
3 290 0-60 0.28
850 -0.05 0.21
77 0.17 0.02
4O O.O4 O.O2
h, specimen of high, low concentration.
11 specimen of low concentration, influenced by h.
13, 14, ls specimen of low concentration, uninfluenced.
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Figure 8. Interference of haemolysis. The hatched zone represents
90 to 110//o recovery of the baseline value. Analytes tested were:
creatine kinase, crealine kinase MB isoform, 7-glulamyltransferase,
crealinine, total protein, uric acid, and fruclosamine.
bilirubin concentrations above 120 gmol/1 and 140 gmol/1,
respectively (figure 7). Similar effects have been observed
on other BM/Hitachi instruments [3].
Haemolysis caused interference with four of the methods
tested (figure 8). Activities ofcreatine kinase and creatine
kinase MB isoform were increased while that of 7-
glutamyltransferase decreased. The protein assay gave
positive bias with haemolysis at high haemoglobin
concentrations > 4 g/l).
Two of the 16 methods evaluated were susceptible to
interference by lipaemia (figure 9). While immuno-
globulin A concentration was increased, an opposite effect
was observed on the activities of aspartate aminotrans-
ferase. A slight increase was also observed in concen-
trations of C-reactive protein (+ 12) at high concen-
trations of triglycerides > 1500 mmol/1).
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Figure 9. Interference of lipaemia. The hatched zone represents
90 to 110% recovery of the baseline value. Analytes tested."
pancreatic amylase, aspartate aminotransf erase, calcium, cholesterol,
iron, sodium, potassium, chloride, C-reactive protein, immuno-
globulin A, transferrin, ferritin, phenobarbital, phenytoin,
lheophylline, and digoxin.
Accuracy
Interlaboratory survey and quality control
Five of the six laboratories participated in an inter-
laboratory survey in which the concentrations of 15
analytes were determined on BM/Hitachi 911 and on the
comparison instruments using one control serum (see table
10, appendix). Results were defined as being acceptable
if their deviations from the target values did not exceed
by more than ___
5 for classical analytes and __+ 10 for
the homogeneous immunoassays.
As shown in figure 10, all values measured on BM/Hitachi
911 fulfilled the acceptance criteria except cholesterol,
iron and uric acid. Decreased values were found for
cholesterol and iron in two laboratories on BM/Hitachi
911, whereas acceptable results were obtained on the
comparison instruments. Slightly increased uric acid
values +6) were measured in one of three laboratories
on BM/Hitachi 91 1.
Similar results were obtained in the quality control study
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Figure 10. Inlerlaboralory survey using a control serum with
concentrations unknown to the evaluators. Each symbol represents
lhe median from measurements performed over 10 days in one
laboratory. Results on BM/Hitachi 91"1 (dashed bars) and on the
comparison instrument (open bars) are shown.
with three control sera (see table 11, appendix). In
addition, the recovery of pancreatic amylase in one
control (106"6%) exceeded the predefined limit.
In the quality control study, recovery experiments with
the CEDIA> assays tbr therapeutic drug monitoring, and
with urine as sample material, were also included. The
recovery of phenobarbital and phenytoin was within the
acceptance criterion of 10 at the target value, whereas
that of theophylline was 88 in one control serum with
a concentration below the therapeutic range, in one of
three laboratories on both BM/Hitachi 911 and on the
comparison instrument. This effect was not confirmed in
a satellite study in which a recovery of98"4 was obtained
using the same control material.
In control urines, all analytes met the acceptance criteria,
except creatinine, for which, in one control urine, a
recovery of 106"9o was obtained on BM/Hitachi 911 and
ot" 110"4 on the comparison instrument. In the other
two control urines, the recovery on BM/Hitachi 911 was
between 90 to 95.
Method comparison
In total, 74 method comparison studies were performed
using fresh human sera or urines; the resulting regression
equations are shown in the appendix (table 12). All
method comparisons were presented graphically and
assessed by the evaluators.
For the determination ofenzymes and substrates in serum
and urine, agreement with the comparison method was
rated as being sufficient if the slope of the regression
equation did not deviate more than 53/o from unity
and the intercept was less than 5 of the diagnostic-
ally important decision levels. The acceptance criteria
were increased to -+-10 slope deviation tbr the homo-
geneous immunoassays. Depending on the analyte,
either the detection limit or a deviation of 10 from
the relrence value were tolerated as intercept for these
assays.
Assessment of electrolyte concentrations in serum is
especially critical. Due to the narrow physiological range
of these analytes, a relatively large confidence interval
for the regression line was obtained. Therefore, method
comparisons were judged by the concentration range in
which the difference between the methods was less than
5%. The comparisons were accepted if less than 5%
deviations were obtained within the following concen-
tration ranges:
(1) Sodium 120-170 mmol/1
(2) Potassium 2- 10 mmol/1
(3) Chloride 80-130 mmol/1.
As examples, six method comparisons comprising three
constituents of serum (creatine kinase, iron, potassium),
one of urine (sodium) and two homogeneous immuno-
assays (one turbidimetric protein assay and one CEDIA"
assay) are shown in figure 11.
Method comparisons not fialfilling the acceptance criteria
are listed in table 8. For classical clinical chemistry
analytes in serum, seven comparisons out of 33 did not
meet the acceptance criteria. Two out of 12 method
comparisons in urine were unacceptable. Comparisons of
homogeneous immunoassays included seven protein
assays and 13 drug assays. All method comparisons
fulfilled the acceptance criteria except one tbr digoxin.
One of the 12 method comparisons for electrolytes in
serum (sodium) did not meet the acceptance criteria. The
range in which the results obtained on BM/Hitachi 911
and on the comparison instrument deviated less than5
was 127-194 mmol/1 instead ofthe required concentration
range of 120-170 retool/.
Reliability
Reliability during the evaluation phase was rated with
the aid of a logbook in which any breakdown, deiict,
malfunction or incident of the analysis system was
recorded. Some technical problems occurred during the
evaluation.
The ISE unit at most evaluation sites had problems, ti0r
example noise alarm, air bubbles and crystallization of
potassium chloride at the sipper probe of the dilution
vessel. These resulted in an increased imprecision. A major
modification of the ISE unit at the beginning of the main
trial, which caused some delay in several laboratories,
improved the performance.
No other systematic malfunctions were observed. Single
malfunction episodes occurred with the sample probe and
with the stirrer resulting in both situations in a wrong
home position and a stoppage of the analyser. Software
malfunctions reported during the multicentre evaluation
were corrected in two new system software releases.
Assessment ofpracticability
The practicability of BM/Hitachi 911 was judged in
comparison with the present situation in the individual
laboratories. The median of all laboratories was calculated
from the mean of all scores obtained for each group of
attributes. These results are shown in figure 12.
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Figure 11. Method comparison for some of the analytes in human serum/plasma/urine analysed on BM/Hitachi 91/ and comparison
instruments. Solid lines represent regression equations calculated according to Passing and Bablok [10] and dotted lines y x.
The following regression equations were obtained: CK (N 150),y l’OOx + 0"0; FE (N 150)y l’OOx O’l& K (N 150)
y l’OOx 0"07; NA in urine (N 100)y 0"98x 1"35; Fr (v oo)y 0"93x + 0"33; .DIG (N 100)y 1.03x 0.14.
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Table 8. Individual method comparison results exceeding the acceptance limits.
Regression anlysis
Analyte Unit Slope Intercep
Comparison
method/instrument
7-Glutamyltransferase U/1 0.91 0"20
Calcium mmol/1 1.06 0.11
Cholesterol mmol/1 1.08 0.33
Creatinine gmol/1 1.11 -8.81
Iron tmol/1 0"92 0.17
Iron gmol/1 0.93 0.37
Fructosamine gmol/1 0.98 17.35
Albumin in urine mg/1 1.60 2.46
Albumin in urine mg/1 0.73 1.50
Digoxin ng/ml 0.75 0.06
BM/Hitachi 737
Atomic absorption spectroscopy
BM/Hitachi 704
BM/Hitachi 717
BM/Hitachi 704
BM/Hitachi 747
Reduction of nitroblue
tetrazolium chloride; longer
incubation time
Rate nephelometry
Radioimmunoassay
Fluorescence polarization
immunoassay
When the medians of the scores for BM/Hitachi 911 were
compared with those of the present laboratory situation,
12 of 14 groups of attributes were rated higher for the
new analysis system. Especially high.scores were given for
spatial arrangement, sample processing, reagent handling,
workflow, calibration and versatility. The medians of the
scores for training/operation and maintenance/trouble-
shooting were identical for BM/Hitachi 911 and the
comparison instruments. None of the attributes was rated
lower on BM/Hitachi 911.
More detailed information on the distribution of scores in
relation to the main topics is shown in figure 13. Higher
scores (8 to 10) were given more frequently for BM/Hitachi
911 than for the existing laboratory situation. For
BM/Hitachi 911, out of 194 attributes 12 were rated with
a score of 0 to (each by only one evaluation site) and
93 attributes with a score of 9 or 10 (each by one or
several laboratories).
Discussion
The versatility of the BM/Hitachi 911 analysis system was
tested in the multicentre study in different laboratory
sections--routine, STAT, homogeneous immunoassays
and urinalysis. The results were assessed on the basis of
quality specifications tbr the various performance charac-
teristics previously agreed upon by the group of evaluators.
A good pertbrmance was found for most of the analytes
in all laboratory sections using different sample materials
of serum, plasma and urine. Although some analytes did
not fulfill one or the other acceptance criterion, none
could be rated unacceptable. The results outside the
acceptance criteria are discussed below with the exception
of the enzymatic methods for determination of sodium,
potassium and chloride. The performance of these
methods was unacceptable on the BM/Hitachi 911. New
standardization procedures for these tests are under
development.
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Figure 12. Assessment of practicability of the BM/Hitachi 911
analysis system (solid line) compared to the laboratory situation
(dashed line). The median of the scores is shown.
Within-run imprecision
The results for control and human materials (see table 5)
show. that overall the instrument had given a good
performance. The individual CVs of a few analytes were
slightly higher than the acceptance limits. These were
found mainly in one laboratory and in one control
material. Variable results were obtained for urinary
albumin in a control material with a concentration below
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Figure 13. Assessment ofpracticabili.. Distribution of scores for the main groups installation, organization of work, quality assurance
and miscellaneous. Dashed bars, represenl the grading for the BM/Hitachi 911 and open bars that of the present laboratory situation.
the decision level (CV vMues of 2"1I, 2"2: and 9"2% at
15 mg/1). This variation in results could not be reproduced
in a human urine pool with’ an albumir concentration of
33 rag/1. With this material:,, a CV of 1"4 was obtained
(see table 5).
Belween-day imprecision
Individual CV values of several analytes exceeded the
acceptance limits. For calcium, cholesterol and creatinine
the maximum CVs ot" 3"1 and 3"3 may still be seen as
borderfline cases. The maximum CVs of 3"73/0 for sodium
and 2"3 for chloride reflected the condition of the ISE
unit which had to be modified during the evaluation. In
spite of this modification, an improvement was not
observed in all laboratories. In one laboratory, the
CEDIA :"> Phenytoin and Digoxin assays, and the urinary
albumin assay in the low level control, also showed CV
values slightly higher than 10.
Quality speccalions
Comparing the between-day imprecision results of the
BM/Hitachi 911 with the proposed quality specifications
tbr the imprecision of analytical systems tbr clinical
chemistry [12, 13], it was concluded that the BM/Hitachi
911 analysis system achieved these specifications for nearly
all analytes evaluated in the study (table 9). The proposed
quality specifications were not met with the calcium assay
(interim specification 1"5, BM/Uitachi 911 1"6%),
creatinine assay (specification 2"2, BM/Hitachi 911
2"3%), sodium assay (interim specification 0"7%, BM/
Hitachi 911 1"4%) and the chloride assay (interim
specification 1"0%, BM/Hitachi 911 1"7%). However,
since the imprecision of the calcium and the creatinine
assay were only 0"1 higher than the specifications, the
results obtained can be judged acceptable. Owing to
the low biological variation of sodium and chloride, the
imprecision specifications were set very low: 0"3 for
sodium and 0"7% for chloride. Since no available tech-
nology is capable of producing such a low imprecision at
a reasonable cost, interim specifications with 0"7 and
1"0 were proposed. Even these values are unlikely to be
easily achieved with the existing technology.
Analylical range limits
The acceptance criteria tbr linearity of the measuring
range were fulfilled for all analytes, except for urinary
albumin at concentrations below 25 mg/1. This non-
linearity resulted in an underestimation of about 3 mg/1
albumin at the decision level of 20 mg/1. This is within
the range found during the multicentre evaluation tbr the
albumin test [14]. In view ofthe large biological variation
of this analyte, this deviation was considered acceptable.
During the evaluation, single-point calibration had been
used for the C-reactive protein assay. This mode of
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Table 9. Comparison of quality specifications for between-day imprecision and inaccuracy proposed by Fraser et al. [12 and 13] with
the results of the BM/Hitachi 911; in parentheses interim specifications. The data of BM/Hitachi 911 were obtained with Precinorm(R)
U, except for TF, IGA (Precinor,m (R) Protein) and drugs (Precinorm
(R) TDM level 3).
Analyte
Quality specifications BM/Hitachi 911 Quality specifications BM/Hitachi 911
between-day between-day inaccuracy mean recovery
CV () CV () ( deviation) (% deviation)
PAMYL 3.7 1.5 6.5 6.6
ASAT 7.2 1.9 6"2 3.4
CK 20.7 1.3 19.8 1.9
GGT 7.4 2"3 21.8 2.6
CA 0.9 (1.5) 1.6 0.7 (1.a) 1.8
CHOL 2.7 1.6 4.1 6.7
CREA 2.2 2.3 2.8 (4.4) 1.1
FE 15.9 2.1 8.9 4.5
TP 1.4 1.1 1.5 (2.8) 1.4
UA 4-2 1.3 4.0 (8.4) 5.9
NA 0.3 (0-7) 1.4 0.2 (0.6) 0.5
K 2.4 1.8 1.6 (4.8) 1.0
CL 0.7 (1.0) 1.7 0.5 (1.4) 0-6
TF 2.4 (4.0) 1.5 2.3 (4.8) 5.4
IGA 2.2 (3.8) 9.9 12.5 3.2
DIG 3.8 (4.7) 3.7 3.9 1.6
THEO 11.1 2.4 5.4 2.8
PHEBA 2.2 2.2 5.6 2.0
PHENY 3.6 3.3 4.1 4.3
calibration gave an upper limit of the analytical range of
80 mg/1 which is not sufficient for diagnostic purposes.
However, studies performed during the multicentre
evaluation of the C-reactive protein assay using multi-
point calibration showed a higher measuring range at
least up to 250 mg/1 [15-1, or even higher, depending on
the standards used. Therefore, only multi-point calibration
is recommended now by the manufacturer, and the results
obtained during this evaluation are not reported.
lnlerf erences
Increased total protein values were measured at haemo-
globin concentrations above 4 g/1. This can be readily
explained by the ttct that haemoglobin is a protein. The
activity of/-glutamyltransferase was decreased in haemo-
lytic samples. As a consequence, the 7-glutamyltransferase
test will be modified by the manufacturer in order to
reduce this interference. Increased activities of creatine
kinase, and especially creatine kinase MB isoform, were
found in the presence of haemoglobin. This is caused by
the release of adenylate kinase from erythrocytes. Again,
the manufacturer intends to modify the application for
the creatine kinase MB isoform assay, with the aim of
reducing the susceptibility of the method to interference
by haemoglobin.
Increased immunoglobulin A concentrations had been
measured in lipaemic samples. Theretbre, a modified
immunoglobulin A assay is presently being developed to
overcome this problem. The effect of turbidity on
aspartate aminotransferase activities has previously been
observed during other BM/Hitachi system evaluations
I-3-1. It can be explained by the fact that the fresh reagents
tbr this assay have high initial absorbance and that the
addition of a turbid specimen would cause the total
absorbance to exceed the photometric measurement range
of 3"3 absorbance units.
Avcuracy
During the interlaboratory survey and the quality control
study a recovery ofless than95 was found for cholesterol.
The assigned value of this analyte was confirmed by the
reference method of isotope dilution/mass spectrometry
[16]. Therefore, the effect could not be attributed to a
wrongly assigned value. In two of the three method
comparison studies a good agreement was found, whereas
in the third increased cholesterol values were obtained on
BM/Hitachi 911. These contradictory results could not
be explained. The effect was not observed in a satellite
study performed in one of the evaluation centres.
Iron values below the acceptance criteria were found in
three of the four control sera used in the interlaboratory
survey and the quality control study. The effect was
confirmed in the method comparison study in two of the
three laboratories (table 8). In the third laboratory, in
which the comparison instrument was a centrifugal
analyser, a slope of 1-00 and an intercept of-0"15 gmol/1
iron were obtained in the regression analysis. The deviant
results were probably caused by wrongly low values being
assigned to the calibrators of the two comparison
instruments.
If the results of the accuracy experiments are compared
to the quality specifications proposed by Fraser el al. [12,
13], all assays performed on BM/Hitachi 911 met the
requirements with the exception of cholesterol and
transferrin.
Eleven out of 74 method comparisons gave slope intervals
and intercepts that were outside the acceptance limits
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(table 8). Differences in the 7-glutamyltransferase assay
were caused by an incorrect temperature conversion factor
on the comparison instrument in one laboratory. The
method comparison tbr the calcium assay yielded a slope
of 1"06. However, the differences between the values of
individual samples (from -0"13 to 0"18 mmol/1) were
acceptable. In one of three laboratories a slope of 1"11
was obtained in the method comparison for creatinine.
In spite of this, agreement was present at the decision
level. However, with this high slope, results of samples
tiom dialysis patients are not correctly interpreted. In a
satellite study in one of the laboratories, the deviation was
confirmed. The manufacturer will change the application
in order to correct the discrepancy. The lack ofagreement
in the tiustosamine assay could be explained by the fact
that the comparison method was performed with a longer
incubation time. The evaluators accepted this deviation.
Albumin in urine showed discrepant results in two of the
three laboratories where the assay was compared with
nonturbidimetric methods. One out of the four digoxin
method comparisons was outside the accepted range. The
experiment had been pertbrmed in a laboratory where
many samples were derived from haemodialysis patients.
These samples might contain digoxin-like immunoreactive
thctors which are known to interfere digoxin assays [ 17].
The results ot’the C-reactive protein method comparisons
are not reported because single-point calibration used in
the experiments had much narrower linear range than
was originally thought. ThereIbre, the application was
later changed to multi-point calibration.
Praclicabiliy
The outstanding tiature of the BM/Hitachi 911 analysis
system is that it can be used as a consolidated workstation
tbr assays from diverse segments of a clinical laboratory
(clinical chemistry, proteins, therapeutic drug monitoring).
All tests necessary tbr a complete patient profile can be
pertbrmed using one primary tube without sample
splitting and additional manual workload. This simplifies
the distribution ofsamples and thus the organization ofthe
laboratory. Hazards ot’sample mix-up as well as cost for
sample splitting are avoided. Moreover, analyses requiring
a predilution step (tbr example, immunoglobulins) can
also be handled easily without the need for high sample
volume. The analyser pertbrms the predilution itself.
Urine samples can be run randomly in series with serum
or plasma specimens on BM/Hitachi 911. No relevant
carry-over effects between the different sample materials
were observed during the multicentre evaluation. An
excellent analytical pertbrmance was obtained for urine
samples, showing that the instrument is well suited for
urinalysis.
Suitability of BM/Hitachi 911 for routine analyses
depends, of course, on the size of the laboratory. One of
the evaluators considered the instruments well suited
the routine requirements of his laboratory. The STAT
facilities were rated positively in all evaluation centres.
The acceptance criteria tbr the analytical pertbrmance of
the Boehringer Mannheim/Hitachi 911 analysis system
were thlfilled tbr all laboratory segments with only a few
exceptions. Moreover, the practicability of this instrument
exceeded the requirements for most of the attributes.
Owing to its versatility, the instrument is best placed as
a consolidated workstation in the. small- to medium-sized
laboratory, or as a back-up instrument for special
determinations like proteins, drugs or urinalysis in a
large laboratory.
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Appendix
Table 10. Control and calibration materials.
Calibrator/control material Lot No.
Calibrator for automated systems,
C.f.a.s. (lyophilized)
Calibrator for automated systems,
C.f.a.s (liquid)*
ISE Compensator
Precimat (R) Fructosamine
Preciset(R) MAU
Precimat(R) BNAG
Precimat’ CRP
Precimat (R) IGA
Precimat Transferrin
Preciset(R) Ferritin
Calibrator low/high THEO
Calibrator low/high PHEBA
Calibrator low/high PHENY
Calibrator low/high DIG
Precinorm (R) U
Precipathe U
Precipath
(R) Evaluation*
Precinorm Fructosamine
Precipath Fructosamine
Precinorm’ MAU
Precipath MAU
Precinorm :- NAG
Precinorm -’ Protein
Precinorm TDM
Precinorm: TDM 3
(Boehringer Mannheim GmbH,
Mannheim, Germany)
Interlaboratory survey
Precinorm.-,’ U
C.f.a.s. Proteins
Lyphochek
,!’
Quantitative urine control normal
level (Bio-Rad Laboratories,
M/inchen, Germany)
172219
176 286
636238
172O78
176872
628 755
17463802
17420001
172644701
173223
A 7601 C/A 7602 C
A 7735 B/A 7736 B
A 7502 B/A 7511 B
A 7667 B/A 7668 B
169 151
173579
174412
175 900
171 630
175221
175 367
628 757
177031
17505090
17505290
168 588
178 586
52201
* Only for evaluation purposes.
Table 11. Imprecision and recovery of all laboratories in individual control materials on the BM/Hilachi 911.
Between-day Within-run
Mean recovery CV CV
Analytc Assigned
[unit] Control material value Median Range Median Range Median Range
PAMYL Precinorm" U 385 106.6 104.5-107-0 1.5 1.5-2.9
[U/1] Precipath" U 518 102.4 99.2-103.1 1.1 1.0-2-9
Precipath" Evaluation 504 100.4 99.3-102.0 1.7 1.3-2.4
ASNI" Precinorm’" U 53 103.4 97.3-104.6 1.9 1.3-2.7
[U/1] Precipath" U 125 100.5 94.8-100.7 1.4 1-0-1.5
Precipath" Evaluation 90 100.9 97.8-103.0 1.8 1.5-2.1
CK Precinorm" U 258 98.1 97.4-103-5 1.3 1.0-1.3
[U/1] Precipath" U 471 98.7 98.1-103.8 1.2 0.7-1.2
Precipath" Evaluation 322 102.2 100.6-106.8 1-2 0.8-1.5
GC;I" Precinorm" U 62 97.4 95.5- 9.8.2 2"3 1.6-2.4
[U/1] Precipath" U 189 99.0 97.4-101.0 1.7 1.4-2.0
Precipath" Evaluation 102 100.7 98.2-102.5 1.7 1.5-1.7
0.6 0.6-1.2
0.8 0.7-0.8
1.0 0.8-1.1
1.6 1.2-2.2
0.8 0.8-0.9
1.3 1.2-1.4
0.9 0.8-1.2
0.7 0.5-1.6
1.1 0.7--1.6
1.1 1.0-1.4
O.5 O.5-0.8
0.8 0.7-1.0
(continued)
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Table 11 (continued).
Between-day Within-run
Mean recovery CV CV
Analytc Assigned
[unit] Control material value Median Range Median Range Median Range
CA
[mmol/1]
CHOL
[mmol/1]
CREA
[gmol/1]
FRUCT
[lamol/1]
FE
[gmol/1]
TP
[g/1]
UA
[-tmol/1-]
NA
[mmol/1]
K
[mmol/1]
CL
[mmol/1]
CRP
[mg/1]
IGA
[g/1]
F’I’
[gg/1]
TF
[-g/l]
PHEBA
[gg/ml]
PHENY
[gg/ml-]
THEO
[gg/ml]
DIG
[ng/ml]
[u/q
CREA
(.Urine)
[mmol/1-]
206
Precinorm U
Precipath’ U
Prccipath
(R) Evaluation
PrecinormR U
Precipath U
Precipath Evaluation
Precinorm(R) U
Precipath
(R) U
Precipath
(R) Evaluation
Precinorm’ Fructosamine
Precipath (R) Fructosamine
Prccinorm(R) U
Precipath’ U
Precipath
(R) Evaluation
Precinorm U
Precipath-
U
Prccipath
(R) Evaluauon
Precinorm (R) U
Precipath
(R) U
Precipath Evaluation
Precinorm U
Precipath U
Precipatht Evaluation
Precinorm U
Precipath U
Precipath
(R) Evaluation
Precinorm c-’ U
Precipath U
Precipath Evaluauon
Prccinorm Protein
Precinorm (R) U
Precinorm ’-" Protein
Precinorm (R) Protein
Precinorm (R) U
Precinorm (R) Protein
Prccinorm (R) TDM
Precinorm (R) TDM 3
Precinorm TDM
Precinorm (R) TDM 3
Prccinorm ’-e TDM
Precinorma’ TDM 3
Precinorm: TDM
Precinorm (R) TDM 3
Prccinorm ’:e BNAG
Lyphochck*
Precinorm ’-" MAU
Precipath MAU
2.3 101.8 100.4-103.5 1-6 1-4- 2.7
3.5 100.0 99.7-102.1 2-0 1.4- 2.5
2.4 101.3 101.3-101.3 1.7 1.4- 3.1
2.9 93.3 87.7- 95.5 1.6 1.2- 2.6
3.2 89.3 80.3- 91.8 2-6 2.3- 3.1
4.0 96-1 92.9- 98.5 2.1 1.5- 2.4
190 101.1 100.1-101.4 2.3 1.5- 2.5
344 98.3 97.1-100.2 2-7 1-7- 3.1
163 94.8 94.4- 96.0 2.9 1.7- 3.3
287 96-8 3.1
552 101.1 2.O
19.5 85.5 84.7- 86.2 2.1 1-4- 2.2
24.6 94.6 92.8- 95.9 2-2 2.0- 2.3
32.7 97.1 96.5- 98.2 1.9 1.3- 2.5
51 101.4 100.6-102.4 1.1 1.0- 1.1
42 105-0 103.8-106-0 1.4 1.1- 1.5
52 104-1 102.9-104.5 1.4 1.2- 1.5
289 105.9 105.6-108.3 1-3 1.2- 2.6
589 102.5 102.4-104.6 1-3 1.0- 1.7
247 103.8 103.2-106-9 1.5 1.3- 2.9
129 99.5 98.2-101.3 1-4 1.4- 1.4
135 100-1 100.1-101.7 1.4 1.3- 1.9
84 101.7 96-4-101.7 2.6 2.3- 3.7
4.9 99.0 98.5-101.0 1.8 1-0- 2.0
6.6 100.8 100.1-102.4 1.7 1.5- 1.9
4.6 101.1 100.5-101.5 1.6 1.3- 2.0
85
105
101
49
1.8
3.6
95
2.3
4.5
6.1
49.2
4.4
25.4
5.0
25.3
0.95
3.2
7.7
16.1
4.3
100.6 98.0-101.2 1.7 1-6- 2.3
103.5 100.5-104.6 1.7 1.6- 2.3
96.4 95.0- 97.3 1-8 1.6- 2.3
102.7 100.7-104.6 2.6 0.8- 4.7
1.4 0.7-1.5
0.8 0.7-0-8
0-8 0.8-1.5
1.6 1.2-1.9
1.6 1.1-1-8
2-0 1-5-2.1
1.6 0.9-1.6
1.0 0.8-1.5
1.4 1.4-1.5
1.0 0.7-1.1
0.9 0.8-1-0
1.8 1.3-3.1
1.3 0.9-1-5
0.9 0.9-1.5
0.5 0.4-1.5
0.8 0.4-1.1
0.7 0.5-1.4
0.6 0.4-0.7
0-5 0.5-0.8
1-0 0.9-1.0
0-7 0.4-1.0
0.4 0.3-1.0
1-0 0-5-1-3
0.8 0.3-1.1
0.6 0.4-1.4
0.7 0.5-1.3
1.1 0.5-1.2
0.5 0.4-0.7
0.7 0.6-0.8
1.3 0.8-1.8
96.9- 97.8 1.3- 2.3 1-9-2.0
96.8- 96.8 0.7- 1.5 0-9-1.4
102.0 2.8
98.0 6.9
94.6 2.9
103.3 96.7-103.3 6.0 3.1- 6.4
97.8 95-6-102.0 2.2 1. l- 2-9
106.8 95.5-106.8 6.6 4.6-11.7
95.7 94-9- 96-1 3.3 2-3- 4.0
94.0 88-0- 96.0 4.2 3.6- 5.7
97.2 93-7- 98.4 2.4 2.4- 2.5
101.1 91.6-110.5 9.4 6.9-10.2
98.4 95.0-104.5 3.7 1.6- 4.3
1.1
1.6 1.3-3.5
3.0 2.0-3.0
1.5 1.4-1-9
3.9 2.9-4.2
1.7 1-7-1.8
5.9 5.6-8.4
2.6 2.1-4.5
4.8 4.3-4.8
2.1 2.0-2.3
7.6 6.5-8.8
3.5 2.4-4.0
0.9 0.8-1.1
101.4-106.9 1.6- 3,7 1.3-1.7
90.7- 92.8 0.9- 3.3 1.1-1.2
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Table 11 (continued).
Between-day Within-run
Mean recovery CV CV
Analyte Assigned
[unit] Control material value Median Range Median Range Median Range
MAU Precinorm (R) MAU 15.5 90.9
(Urine) Precipath
(R) MAU 94.8 96.7
[mg/1]
NA Lyphochek
(R) 60 99.8
(Urine)
[mmol/1]
K Lyphochek
(R) 23 103.3
(Urine)
[mmol/1]
CL Lyphochek
(R) 53 94.8
(Urine)
[mmol/1]
89.7- 94.2 3.3 2.7-11.3 2"2 2.1-9.2
93.3- 97.8 1.6 0.8- 3.5 1.1 0.8-2.0
1.6 0.4 0.4-0.5
1.7 0.2 0.2-0.3
"2 0.4 0.4-0.5
Table 12. Method comparison for human serum/plasma/urine analytes assayed on BM/Hitachi 911 ) ,and,the comparison instrument
(x). Each line represents the result from one laboratory.
Regression analysis
y=bx+a
Sample Range
Analyte (Unit) material N (from x) b
95,?/o
Median
distance
[9]
PAMYL (U/l) Serum 150 8 to 727 1.02
Plasma 105 5 to 684 1.01
Serum 225 28 to 2010 1-01
ASAT (U/l) Serum 150 9 to 642 1-03
Plasma 105 10 to 549 0.99
Serum 211 10 to 620 1.01
CK (U/l) Serum 146 3 to 763 1.01
Serum 150 6 to 1270 1.00
Plasma 150 5 to 1060 1.03
CK-MB (U/l) Serum 150 3 to 116 0.95
Plasma 100 5 to 443 0.99
GGT (U/l) Serum 147 3 to 1170 0.91
Serum 149 0 to 593 1.00
Plasma 150 6 to 1225 1.04
CA (mmol/1) Serum 150 1.5 to 2.9 1.06
Plasma 105 2"0 to 3.0 0"96
Serum 212 1.4 to 3.5 1.00
CHOL (mmol/1) Serum 150 0.9 to 10.0 1.08
Plasma 105 1.0 to 8.2 1.01
Serum 150 1.4 to 13.9 1.01
CREA (lamol/1) Serum 149 23.9 to 1775 1.04
Serum 150 34.0 to 1169 1.11
Plasma 150 47,0 to 648 i.02
FE (gmol/1) Serum 150 1.0 to 45 0.92
Plasma 90 0.4 to 48 0.93
Serum 150 1.9 to 76 1,00
FRUCT (gmol/1) Plasma 100 143 to 626 0.98
TP (g/l) Serum 147 38 to 81 1-04
Serum 150 42 to 117 1.04
Plasma 150 34 to 91 1.05
UA (gmol/1) Serum 149 59 to 987 1.01
Serum 150 68 to 1034 1.05
Plasma 150 76 to 834 1.00
-1.27
-0.79
-2.59
0.33
-1.16
0.24
1.45
0.06
-0.39
1.02
-0.10
O.2O
0-00
0.43
-0.11
0.06
-,O-O2
-0.33
-0.01
0.00
0.4
-8.81
-6.81
0.17
0.37
-0.15
-17.35
-0.30
0-02
1.48
12.03
-16.33
-3.83
6.3
17.3
32.9
2"2
3.4
9.3
5.6
6.1
8.7
2’8
10.7
3.4
0.1
15"5
0.09
0.05
0.11
0.15
O-25
0.24
18.0
11.5
13.1
0.5
1.1
1.1
19.4
1.5
2"2
2.7
2O’2
46.6
30’2
(continued)
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Table 12 (continued).
Sample Range
Analyte (Unit) material 3/ (from x)
Regression analysis
y=bx+a
b a
95?/0
Median
distance
fg]
NA (mmol/1) Plasma 90 130 to 149
Plasma 90 129 to 149
Serum 75 119 to 152
Serum 75 131 to 151
K (mmol/1) Plasma 90 3.20 to 5"20
Plasma 150 2.91 to 5-22
Serum 75 1.90 to 7.99
Serum 75 3.4 to 6.51
CL (mmol/1) Plasma 90 93 to 114
Plasma 90 93 to 112
Serum 75 80 to 119
Serum 74 84 to 112
IGA (g/l) Serum 100 1.00 to 2.46
Serum 99 0.42 to 64.32
FT (gg/1) Plasma 100 6 to 518
TF (g/l) Plasma 90 1.00 to 6.00
PHEBA (gg/ml) Plasma 70 1"2 to 59.6
Serum 98 1.0 to 43.3
Serum 80 12.4 to 45.2
PHENY (gg/ml) Plasma 70 1.4 to 28.9
Serum 99 0.3 to 60.2
Serum 79 3.5 to 24.4
THEO (gg/ml) Plasma 70 2"0 to 62"0
Serum 100 0.3 to 26" 7"
Serum 50 2"1 to 23.4
DIG (ng/ml) Serum 98 0"0 to 4.4
Plasma 100 0.3 to 3.5
Serum 100 0.1 to 4.3
Serum 80 0.4 to 4.4
BNAG (U/l) Urine 100 0.5 to 7.5
CREA (mmol/1) Urine 100 2"3 to 29"2
Urine 100 1.5 to 18.8
MAU (mg/1) Urine 100 1.5 to 1365
Urine 90 0.0 to 67
Urine 94 2"0 to 58
NA (mmol/1) Urine 100 16 to 314
Urine 100 9 to 230
K (mmol/1) Urine 100 8 to 94
Urine 100 8 to 92
CL (mmol/1) Urine 100 12 to 286
Urine 100 5 to 246
1.24 -36"79
1.18 -28.03
1.07 -8"75
1.17 -26.35
1.05 -0.36.
1.00 -0-07
1.00 0.04
1.04 -0"2
1.03 -2"63
1.12 10.10
1.01 -0.63
1.13 -10.71
"00 0.03
"00 0.00
0.93 0.33
0.95 0.14
1.00 -0.60
0.95 -0.96
1.08 2.44
1.01 -0.59
1.00 0" 71
1.03 1.49
1.06 -0.18
1.08 -0.21
1.04 -0"52
0.75 -0.06
1.03 -0.14
O.96 O’O3
1.03 -0.09
1.01 0.07
1.00 -0.15
1.00 -0"20
1.01 0.26
0"73 1.49
1.60 -2.46
1.00 0.39
0.98 1.35
0.99 0.05
O’99 O.24
1.01 -2"03
"00 5"90
2.68
2"O9
2.17
1.67
0.17
0-13
0.11
0.39
2"2O
2.44
1.88
6.17
0.03
0.55
25"9
O’28
1.63
1.92
2"42
1.46
1’72
1.55
0"98
0.77
1.59
0"76
0.18
0.35
0.40
0.10
O’22
O.50
1.05
3.09
2"65
2"5
4.1
1.3
2"2
2"6
11.5
208